Cited by 90Menopause: Health Impacts and TreatmentsDementia and Cognitive Impairment ResearchEstrogen and related hormone effects

Postmenopausal hormone therapy, timing of initiation, APOE and cognitive decline

Open access
Kang, Jae H., Grodstein, Francine·2012·Neurobiology of Aging

Abstract

Associations between postmenopausal hormone therapy (HT) and cognitive decline may depend on apolipoprotein E (APOE) status or timing of initiation. We included 16,514 Nurses' Health Study participants aged 70-81 years who were followed since 1976 and completed up to 3 telephone cognitive assessments (2 years apart), between 1995 and 2006. The tests assessed general cognition (Telephone Interview of Cognitive Status; TICS), verbal memory, and category fluency. We used longitudinal analyses to estimate differences in cognitive decline across hormone groups. APOE genotype was available in 3697 participants. Compared with never users, past or current HT users showed modest but statistically significant worse rates of decline in the TICS: the multivariable-adjusted difference in annual rate of decline in the TICS among current estrogen only users versus never users was -0.04 (95% confidence interval, -0.07 to -0.004); for current estrogen + progestin users, the mean difference was -0.05 (95% confidence interval, -0.10 to -0.002). These differences were equivalent to those observed in women who are 1-2 years apart in age. We observed no protective associations with early timing of hormone initiation. We found suggestive interactions with APOE e4 status (e.g., on TICS, p interaction, 0.10), where the fastest rate of decline was observed among APOE e4 carriers who were current HT users. Regardless of timing of initiation, HT may be associated with worse rates of decline in general cognition, especially among those with an APOE e4 allele.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.neurobiolaging.2010.10.007

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • It is unclear whether the influence of APOE-e4 may depend on the sex hormone estrogen.

    “It is unclear whether the influence of APOE‐e4 may depend on the sex hormone estrogen.”

    From 2024 Alzheimer's disease facts and figures (2024) · cites this paper as [316]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Kang, J. H., & Grodstein, F.
Affiliations
Brigham and Women's Hospital (US)
Venue
Neurobiology of Aging
Publisher
Elsevier BV
Published
2012-07
Volume
33
Issue
7
Pages
1129-1137
ISSN
0197-4580 (ISSN-L)
OpenAlex
W2058183801
Cited by
90
References
50
Citations by year
2026: 10 · 2025: 6 · 2024: 7 · 2023: 4 · 2022: 7 · 2021: 11 · 2020: 6 · 2019: 5 · 2018: 7 · 2017: 1 · 2016: 8 · 2015: 3 · 2013: 9 · 2012: 6
FWCI
3.62
Type
journal article
Language
en
Open access
Locations
  • Neurobiology of Aging (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Institutes of Health (AG15424, AG13483, CA87969)
  • Wyeth Pharmaceuticals (0712X1-4416)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Estrogen and related hormone effects
Keywords
hormone replacement therapy, cognitive decline, apolipoprotein E, APOE ε4, estrogen, estrogen plus progestin, global cognition, verbal memory, semantic fluency, older women, Nurses' Health Study
MeSH terms
Adult, Aged, Aged, 80 and over, Cognition Disorders, Drug Administration Schedule, Estrogens, Female, Follow-Up Studies, Genetic Markers, Humans, Longitudinal Studies, Middle Aged, Neuropsychological Tests, Surveys and Questionnaires, Time Factors, Estrogen Replacement Therapy, Postmenopause, Apolipoprotein E4

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review